Skip to content

Home
About Us
Oncology
Preclinical Services
Shareholders
News & Resources
Contact Us
English

Menu

Home
About Us
Oncology
Preclinical Services
Shareholders
News & Resources
Contact Us
English

Response to ASX Appendix 4C Query

May 11, 2017

Response to ASX Appendix 4C Query

Categories ASX Announcements, Financial Reports

Post navigation

A*STAR TV Business Insider – The Story of Invitrocue

Invitrocue Expands Into In-Vitro Skin and Wound Healing Assays

Search for:

Recent Posts

Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean
Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology
Operational Updates – February 2024
Operational Updates – October 2023
Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com

SAC - SINGLAS Accredited Laboratory

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2024 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings